EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Advancing Measurable Residual Disease Detection in Pediatric BCP-ALL: Insights from Novel Immunophenotypic Markers

Alexandra Baldzhieva iD, Hasan Burnusuzov iD, Hristina Andreeva iD, Teodora Kalfova iD, Steliyan Petrov iD, Dobrina Dudova, Katya Vaseva, Marianna Murdjeva, Hristo Taskov

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26094282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Alexandra Baldzhieva und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology and Immunology "Prof. Dr. Elissay Yanev", Faculty of Medicine, Medical University-Plovdiv, Vasil Aprilov Str. 15A,…. Hauptthemen laut MEDLINE: Neoplasm, Residual, Immunophenotyping, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: "Strategic Research and Innovation Program for the Development of Medical University-Plovdiv" No BG-RRP-2.004-0007-C01, Establishment of a Network of Research…, Project "National University Complex for Biomedical Applied Research, linked to participation in BBMRI-ERIC" (NUKBPI-BBMRI.BG), Contracts D01-302/2021 and D01-…, Medical University Plovdiv.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Measurable Residual Disease (MRD) assessment in pediatric acute lymphoblastic leukemia (ALL) is crucial for relapse prediction and treatment guidance. Multiparameter flow cytometry (MFC) enhances detection but faces limitations due to insufficient leukemia-associated immunophenotypes (LAIPs) and antigen modulation. This study explores new markers to improve MFC-based MRD detection in B-cell precursor ALL (BCP-ALL). Expression-patterns of seven aberrancy markers, i.e., CD44, CD304, CD73, CD86, CD123, CD99, CD58, and one B-cell maturation marker, CD22, were studied in 143 samples with leukemic-blasts from sixty-one childhood BCP-ALL patients and in hematogones of 20 non-leukemic bone marrow (BM) samples using fourteen-color MFC. The highest relative frequences of LAIPs amounted to 82.50%, reported for CD99 and CD58, followed by CD44 (81.10%), CD73 (76.20%), CD22 (73.40%), CD304 and CD86 (68.50%), while the lowest relative frequence was CD123 (44.40%). Differential expression of CD58, CD304, and CD73 in diagnostic samples was highly significant (p < 0.01) between pre-B-I, pre-B-II, immature B cells, and BCP-ALL blasts. In MRD-positive samples CD73 showed significantly high (p < 0.01) differential expression between all stages of hematogones and residual blasts, followed by CD304, CD58, and CD22. CD73 and CD304 were identified as the most reliable among the tested markers for distinguishing both diagnostic and MRD blasts from normal B cell precursors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm, ResidualImmunophenotypingPrecursor B-Cell Lymphoblastic Leukemia-LymphomaBiomarkers, TumorHumansChildChild, PreschoolMaleFemaleInfantFlow CytometryAdolescentAntigens, CD

Stichwörter der Autor:innen

blastschildhood B-cell precursor acute lymphoblastic leukemiaflow cytometryimmunophenotypingleukemiameasurable residual disease

Substanzen

Biomarkers, TumorAntigens, CD

Autor:innen und Institutionen

  • Department of Medical Microbiology and Immunology "Prof. Dr. Elissay Yanev", Faculty of Medicine, Medical University-Plovdiv, Vasil Aprilov Str. 15A, 4002 Plovdiv, Bulgaria.
  • Research Institute at Medical University-Plovdiv, Vasil Aprilov Str. 15A, 4002 Plovdiv, Bulgaria.
  • Laboratory of Clinical Immunology, St. George University Hospital, Vasil Aprilov Str. 15A, 4002 Plovdiv, Bulgaria.
  • Department of Pediatrics and Medical Genetics, Faculty of Medicine, Medical University-Plovdiv, Vasil Aprilov Str. 15A, 4002 Plovdiv, Bulgaria.
  • Department of Immunology and Molecular Genetics, Laboratory Medicine Division, Diagnostic Clinic, University Hospital of North Norway, Hansine Hansens veg 67, 9019 Tromsø, Norway.

ORCID-Profile: Alexandra Baldzhieva, Hasan Burnusuzov, Hristina Andreeva, Teodora Kalfova, Steliyan Petrov

Förderung

  • "Strategic Research and Innovation Program for the Development of Medical University-Plovdiv" No BG-RRP-2.004-0007-C01, Establishment of a Network of Research…
  • Project "National University Complex for Biomedical Applied Research, linked to participation in BBMRI-ERIC" (NUKBPI-BBMRI.BG), Contracts D01-302/2021 and D01-…
  • Medical University Plovdiv
  • Medical University–Plovdiv through Doctoral and Postdoctoral project
  • “Strategic Research and Innovation Program for the Development of Medical University–Plovdiv”
  • Establishment of a Network of Research Higher Schools, National plan for recovery and resilience
  • European Union–NextGenerationEU
  • Project “National University Complex for Biomedical Applied Research, linked to participation in BBMRI-ERIC”

Zitieren

APA

Baldzhieva, A., Burnusuzov, H., Andreeva, H., Kalfova, T., Petrov, S., Dudova, D., Vaseva, K., Murdjeva, M., & Taskov, H. (2025). Advancing Measurable Residual Disease Detection in Pediatric BCP-ALL: Insights from Novel Immunophenotypic Markers. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26094282

Vancouver

Baldzhieva A, Burnusuzov H, Andreeva H, Kalfova T, Petrov S, Dudova D, et al. Advancing Measurable Residual Disease Detection in Pediatric BCP-ALL: Insights from Novel Immunophenotypic Markers. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26094282

BibTeX
@article{Baldzhieva2025,
  author = {Baldzhieva, Alexandra and Burnusuzov, Hasan and Andreeva, Hristina and Kalfova, Teodora and Petrov, Steliyan and Dudova, Dobrina and Vaseva, Katya and Murdjeva, Marianna and Taskov, Hristo},
  title = {Advancing Measurable Residual Disease Detection in Pediatric BCP-ALL: Insights from Novel Immunophenotypic Markers},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26094282}
}
Kostenlos starten →